Medicus Pharma Ltd Stock Price, News & Analysis

Medicus Pharma Ltd. (NASDAQ: MDCX) announced the voting results from its Annual and Special Meeting held on July 22, 2025. The company notably welcomed two high-profile additions to its Board of Directors: former Congresswoman Cathy McMorris Rodgers, the first female Chair of the House Committee on Energy & Commerce, and Ajay Raju, a prominent attorney and venture capitalist who previously invested $8M in the company's pre-IPO round.

All eight board nominees were elected with overwhelming support, each receiving over 99.8% of votes. Shareholders also approved key measures including the appointment of KPMG LLP as auditors, amendments to company bylaws regarding shareholder meeting quorum requirements, and approval of a Standby Equity Purchase Agreement with YA II PN, Ltd.

Medicus Pharma Ltd. (NASDAQ: MDCX) announced its participation in the BTIG Virtual Biotech Conference 2025, with CEO Dr. Raza Bokhari scheduled for a Fireside Chat on July 30, 2025, at 9:20 a.m. ET.

The company provided updates on its lead asset, SkinJect Inc., which is developing a novel treatment for non-melanoma skin cancer using D-MNA technology. Their Phase 2 study (SKNJCT-003) showed promising interim results with over 60% clinical clearance. The trial has been expanded to 90 subjects and additional European sites. A parallel study (SKNJCT-004) is ongoing in the UAE with 36 patients across four sites.

Additionally, Medicus announced a definitive agreement to acquire Antev Ltd., a UK biotech company developing Teverelix for prostate cancer treatment, with the deal expected to close by August 2025.

Medicus Pharma (NASDAQ: MDCX) has submitted a Type C meeting request to the FDA for October 2025 to discuss their D-MNA (Dissolvable Doxorubicin-containing Microneedle Arrays) development program for treating Basal Cell Carcinoma (BCC).

The company's Phase 2 clinical trial SKNJCT-003 is currently ongoing at 9 U.S. sites, with an expanded enrollment to 90 subjects. A March 2025 interim analysis showed promising results with over 60% clinical clearance. The trial evaluates two dose levels (100μg and 200μg) against a placebo control.

Additionally, Medicus is conducting the SKNJCT-004 trial in the UAE across four sites, targeting 36 patients. In June 2025, the company announced a definitive agreement to acquire Antev Limited, a UK biotech developing Teverelix for prostate cancer treatment.

Medicus Pharma (NASDAQ: MDCX) has announced a definitive agreement to acquire Antev Ltd., a UK-based clinical-stage drug development company. Under the agreement, Antev shareholders will receive a 17% equity stake in Medicus (2,666,600 shares) plus up to $65 million in contingent payments tied to FDA Phase 2 and New Drug Application approvals.

The acquisition centers on Antev's development of Teverelix, a next-generation GnRH antagonist, targeting two key indications: acute urinary retention (AUR) and advanced prostate cancer in cardiovascular high-risk patients. For AUR, Teverelix aims to be first-in-class with a $2B+ annual market opportunity, targeting nearly 1 million annual AUR episodes in the US. The FDA-approved Phase 2b study will involve 390 men across 60-70 US and EU sites.

For advanced prostate cancer, Teverelix targets a $4B+ annual market, specifically focusing on 300,000-500,000 US patients with increased cardiovascular risk. The FDA-approved Phase 2b open-label study will recruit 40 men to evaluate Teverelix as potentially the first hormone therapy specifically labeled for prostate cancer patients with cardiovascular disease history.

The transaction is expected to close by August 2025, subject to Antev shareholder approval and other regulatory requirements. The deal includes a 9-month staggered lock-up period and 36-month voting rights agreement favoring Medicus management.

Medicus Pharma (NASDAQ: MDCX) has appointed Andrew Smith as Chief Operating Officer, bringing over 30 years of experience in asset management and financial operations. Smith previously served as CEO of SR Asset Management until 2024 and held various leadership positions at Aberdeen Asset Management. Additionally, the company reported progress in its SKNJCT-003 Phase 2 clinical study for Basal Cell Carcinoma treatment using Doxorubicin Containing Microneedle Arrays (D-MNA), with over 50 of 90 planned patients enrolled across nine U.S. sites. A March 2025 interim analysis showed promising results with over 60% clinical clearance. The company is expanding trials to Europe and conducting SKNJCT-004 study in UAE with 36 patients. Medicus also announced a binding LOI to acquire Antev Ltd., a UK biotech company developing Teverelix for prostate cancer treatment.

Medicus Pharma (NASDAQ: MDCX) announced that CEO Dr. Raza Bokhari will present at the 2025 Bio International Convention on June 17, 2025, in Boston. The company's main asset, SkinJect, is developing a novel treatment for non-melanoma skin cancer using D-MNA technology, which delivers doxorubicin through dissolvable microneedles. Their Phase 2 study SKNJCT-003 across 9 U.S. sites showed promising interim results with over 60% clinical clearance, leading to an expansion to 90 participants. Additionally, SKNJCT-004 trial is ongoing in UAE across four prestigious medical centers. In April 2025, Medicus entered a binding LOI to acquire Antev Ltd., a UK biotech developing Teverelix for prostate cancer and acute urinary retention treatment.

Medicus Pharma (NASDAQ: MDCX) has submitted a product development plan to the FDA for treating external squamous cell carcinoma (SCC) in horses using their novel Doxorubicin-containing microneedle array (D-MNA) patch. The company received MUMS designation (similar to Orphan Drug status) in December 2024, granting 7-year exclusive marketing rights post-approval. The clinical study SKNJCT-004 will involve 50 horses in a randomized, double-blind trial comparing two D-MNA dose levels against placebo. The market opportunity is estimated at $250 million. The D-MNA technology has shown promising results in human trials, with a Phase 1 study completed in March 2021 showing safety and efficacy, and an ongoing Phase 2 study (SKNJCT-003) demonstrating over 60% clinical clearance in interim analysis. The company is also expanding trials to Europe and UAE, and recently announced plans to acquire Antev Ltd., a UK biotech company developing treatments for prostate cancer.

Medicus Pharma (NASDAQ: MDCX) has successfully closed a $7.0 million public offering of 2,260,000 units at $3.10 per unit. Each unit includes one common share and one warrant exercisable at $3.10 with a 5-year expiration. The proceeds will primarily fund Phase 2 clinical trials for their innovative doxorubicin tip loaded dissolvable microarray needle skinpatch for basal cell carcinoma treatment. The company, through its subsidiary SkinJect, has already completed Phase 1 safety studies with promising results, showing complete response in six participants. Additionally, Medicus recently announced plans to acquire Antev Ltd., a UK biotech company developing Teverelix for prostate cancer and urinary retention treatment, though the deal remains subject to due diligence and final agreements.

Medicus Pharma (NASDAQ: MDCX) has announced a public offering of 2,260,000 units priced at $3.10 per unit, aiming to raise $7.0 million. Each unit includes one common share and one warrant with a 5-year expiration and $3.10 exercise price. The proceeds will primarily fund Phase 2 clinical trials for their basal cell carcinoma treatment using a doxorubicin-loaded dissolvable microarray needle skinpatch. The company may also expand trials to other non-melanoma skin diseases. The offering, led by Maxim Group LLC with co-placement agents Brookline Capital Markets and D. Boral Capital, is expected to close on June 2, 2025. Additionally, MDCX recently announced plans to acquire Antev Ltd., a UK biotech developing Teverelix for prostate cancer and urinary retention treatment, subject to due diligence and approvals.